Wayne Vuong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wayne Vuong has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- John Christopher Vederas
University of Alberta
7 shared publications - Conrad Fischer
University of Alberta
5 shared publications Elena Arutyunova
Department of Biochemistry, Membrane Protein Disease Research Group, University of Alberta, Edmonton AB, T6G 2R3, Canada; Li Ka Shing Institute of Virology, University of Alberta, Edmonton AB, T6G 2E1, Canada
5 shared publications- M. Joanne Lemieux
University of Alberta
5 shared publications - Tess Lamer
Department of Chemistry, University of Alberta, Edmonton, AB, T6G 2G2, Canada
5 shared publications - David Lorne Tyrrell
University of Alberta
4 shared publications
Latest Publications
- Open Access
PSMtags improve peptide sequencing and throughput in sensitive proteomics
Mass spectrometry-based proteomics enables comprehensive characterization of proteins, but label-free approaches are challenging to scale to thousands of samples per day (SPD). Multiplexed data-independent approaches (plexDIA) can increase throughput but lack the mass tags to enable it. Here, we systematically screened a library of 576 compounds and identified several small molecules that, when conjugated to peptides, improve their detection and sequence identification. The lead molecule, PSMtag, substantially increases the detection of fragment b-ions, which increases the confidence of sequence identification and enhances de novo sequencing. PSMtags allow 9-plexDIA, using only stable isotopes of carbon, oxygen and nitrogen. As a result, it allows increasing sample throughput for plexDIA workflows. We demonstrate 1,130 SPD with 9-plexDIA from single-cell-level human proteomes, acquiring 27,520 protein datapoints in the same time label-free methods acquire 3,216. Our approach constitutes an expandable framework for developing mass tags to overcome existing limitations in multiplexed proteomics.
Open AccessPSMtags improve peptide sequencing and throughput in sensitive proteomics
Mass spectrometry-based proteomics enables comprehensive characterization of proteins, but label-free approaches are challenging to scale to thousands of samples per day (SPD). Multiplexed data-independent approaches (plexDIA) can increase throughput but lack the mass tags to enable it. Here, we systematically screened a library of 576 compounds and identified several small molecules that, when conjugated to peptides, improve their detection and sequence identification. The lead molecule, PSMtag, substantially increases the detection of fragment b-ions, which increases the confidence of sequence identification and enhances de novo sequencing. PSMtags allow 9-plexDIA, using only stable isotopes of carbon, oxygen and nitrogen. As a result, it allows increasing sample throughput for plexDIA workflows. We demonstrate 1,130 SPD with 9-plexDIA from single-cell-level human proteomes, acquiring 27,520 protein datapoints in the same time label-free methods acquire 3,216. Our approach constitutes an expandable framework for developing mass tags to overcome existing limitations in multiplexed proteomics.
- 1 October 2021
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 222, 113584
Improved SARS-CoV-2 Mpro inhibitors based on feline antiviral drug GC376: Structural enhancements, increased solubility, and micellar studies
- 1 October 2021
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 222, 113584
Improved SARS-CoV-2 Mpro inhibitors based on feline antiviral drug GC376: Structural enhancements, increased solubility, and micellar studies
- Open Access
- 28 August 2021
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 86 (18) , 13104-13110
Improved Synthesis of a Cyclic Glutamine Analogue Used in Antiviral Agents Targeting 3C and 3CL Proteases Including SARS-CoV-2 Mpro
- 28 August 2021
- Published by American Chemical Society (ACS) in The Journal of Organic Chemistry
- Vol. 86 (18) , 13104-13110
Open AccessImproved Synthesis of a Cyclic Glutamine Analogue Used in Antiviral Agents Targeting 3C and 3CL Proteases Including SARS-CoV-2 Mpro
- 9 July 2021
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 65 (4) , 2905-2925
Peptidomimetic α-Acyloxymethylketone Warheads with Six-Membered Lactam P1 Glutamine Mimic: SARS-CoV-2 3CL Protease Inhibition, Coronavirus Antiviral Activity, and in Vitro Biological Stability
Recurring coronavirus outbreaks, such as the current COVID-19 pandemic, establish a necessity to develop direct-acting antivirals that can be readily administered and are active against a broad spectrum of coronaviruses. Described in this Article are novel α-acyloxymethylketone warhead peptidomimetic compounds with a six-membered lactam glutamine mimic in P1. Compounds with potent SARS-CoV-2 3CL protease and in vitro viral replication inhibition were identified with low cytotoxicity and good plasma and glutathione stability. Compounds 15e, 15h, and 15l displayed selectivity for SARS-CoV-2 3CL protease over CatB and CatS and superior in vitro SARS-CoV-2 antiviral replication inhibition compared with the reported peptidomimetic inhibitors with other warheads. The cocrystallization of 15l with SARS-CoV-2 3CL protease confirmed the formation of a covalent adduct. α-Acyloxymethylketone compounds also exhibited antiviral activity against an alphacoronavirus and non-SARS betacoronavirus strains with similar potency and a better selectivity index than remdesivir. These findings demonstrate the potential of the substituted heteroaromatic and aliphatic α-acyloxymethylketone warheads as coronavirus inhibitors, and the described results provide a basis for further optimization.
- 9 July 2021
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 65 (4) , 2905-2925
Peptidomimetic α-Acyloxymethylketone Warheads with Six-Membered Lactam P1 Glutamine Mimic: SARS-CoV-2 3CL Protease Inhibition, Coronavirus Antiviral Activity, and in Vitro Biological Stability
Recurring coronavirus outbreaks, such as the current COVID-19 pandemic, establish a necessity to develop direct-acting antivirals that can be readily administered and are active against a broad spectrum of coronaviruses. Described in this Article are novel α-acyloxymethylketone warhead peptidomimetic compounds with a six-membered lactam glutamine mimic in P1. Compounds with potent SARS-CoV-2 3CL protease and in vitro viral replication inhibition were identified with low cytotoxicity and good plasma and glutathione stability. Compounds 15e, 15h, and 15l displayed selectivity for SARS-CoV-2 3CL protease over CatB and CatS and superior in vitro SARS-CoV-2 antiviral replication inhibition compared with the reported peptidomimetic inhibitors with other warheads. The cocrystallization of 15l with SARS-CoV-2 3CL protease confirmed the formation of a covalent adduct. α-Acyloxymethylketone compounds also exhibited antiviral activity against an alphacoronavirus and non-SARS betacoronavirus strains with similar potency and a better selectivity index than remdesivir. These findings demonstrate the potential of the substituted heteroaromatic and aliphatic α-acyloxymethylketone warheads as coronavirus inhibitors, and the described results provide a basis for further optimization.
- 1 June 2021
- Published by Elsevier in Journal of Molecular Biology
- Vol. 433 (13) , 167003
N-Terminal Finger Stabilizes the S1 Pocket for the Reversible Feline Drug GC376 in the SARS-CoV-2 Mpro Dimer
- 1 June 2021
- Published by Elsevier in Journal of Molecular Biology
- Vol. 433 (13) , 167003
N-Terminal Finger Stabilizes the S1 Pocket for the Reversible Feline Drug GC376 in the SARS-CoV-2 Mpro Dimer
- Open Access
N-Terminal finger stabilizes the reversible feline drug GC376 in SARS-CoV-2 M pro
The main protease (M pro , also known as 3CL protease) of SARS-CoV-2 is a high priority drug target in the development of antivirals to combat COVID-19 infections. A feline coronavirus antiviral drug, GC376, has been shown to be effective in inhibiting the SARS-CoV-2 main protease and live virus growth. As this drug moves into clinical trials, further characterization of GC376 with the main protease of coronaviruses is required to gain insight into the drug’s properties, such as reversibility and broad specificity. Reversibility is an important factor for therapeutic proteolytic inhibitors to prevent toxicity due to off-target effects. Here we demonstrate that GC376 has nanomolar K i values with the M pro from both SARS-CoV-2 and SARS-CoV strains. Restoring enzymatic activity after inhibition by GC376 demonstrates reversible binding with both proteases. In addition, the stability and thermodynamic parameters of both proteases were studied to shed light on physical chemical properties of these viral enzymes, revealing higher stability for SARS-CoV-2 M pro . The comparison of a new X-ray crystal structure of M pro from SARS-CoV complexed with GC376 reveals similar molecular mechanism of inhibition compared to SARS-CoV-2 M pro , and gives insight into the broad specificity properties of this drug. In both structures, we observe domain swapping of the N-termini in the dimer of the M pro , which facilitates coordination of the drug’s P1 position. These results validate that GC376 is a drug with an off-rate suitable for clinical trials.
Open AccessN-Terminal finger stabilizes the reversible feline drug GC376 in SARS-CoV-2 M pro
The main protease (M pro , also known as 3CL protease) of SARS-CoV-2 is a high priority drug target in the development of antivirals to combat COVID-19 infections. A feline coronavirus antiviral drug, GC376, has been shown to be effective in inhibiting the SARS-CoV-2 main protease and live virus growth. As this drug moves into clinical trials, further characterization of GC376 with the main protease of coronaviruses is required to gain insight into the drug’s properties, such as reversibility and broad specificity. Reversibility is an important factor for therapeutic proteolytic inhibitors to prevent toxicity due to off-target effects. Here we demonstrate that GC376 has nanomolar K i values with the M pro from both SARS-CoV-2 and SARS-CoV strains. Restoring enzymatic activity after inhibition by GC376 demonstrates reversible binding with both proteases. In addition, the stability and thermodynamic parameters of both proteases were studied to shed light on physical chemical properties of these viral enzymes, revealing higher stability for SARS-CoV-2 M pro . The comparison of a new X-ray crystal structure of M pro from SARS-CoV complexed with GC376 reveals similar molecular mechanism of inhibition compared to SARS-CoV-2 M pro , and gives insight into the broad specificity properties of this drug. In both structures, we observe domain swapping of the N-termini in the dimer of the M pro , which facilitates coordination of the drug’s P1 position. These results validate that GC376 is a drug with an off-rate suitable for clinical trials.
- Open Access
- 20 October 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1
Author Correction: Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
- 20 October 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1
Open AccessAuthor Correction: Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
- Open Access
- 27 August 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-8
Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication
The main protease, Mpro(or 3CLpro) in SARS-CoV-2 is a viable drug target because of its essential role in the cleavage of the virus polypeptide. Feline infectious peritonitis, a fatal coronavirus infection in cats, was successfully treated previously with a prodrug GC376, a dipeptide-based protease inhibitor. Here, we show the prodrug and its parent GC373, are effective inhibitors of the Mprofrom both SARS-CoV and SARS-CoV-2 with IC50values in the nanomolar range. Crystal structures of SARS-CoV-2 Mprowith these inhibitors have a covalent modification of the nucleophilic Cys145. NMR analysis reveals that inhibition proceeds via reversible formation of a hemithioacetal. GC373 and GC376 are potent inhibitors of SARS-CoV-2 replication in cell culture. They are strong drug candidates for the treatment of human coronavirus infections because they have already been successful in animals. The work here lays the framework for their use in human trials for the treatment of COVID-19.
- 27 August 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-8
Open AccessFeline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication
The main protease, Mpro(or 3CLpro) in SARS-CoV-2 is a viable drug target because of its essential role in the cleavage of the virus polypeptide. Feline infectious peritonitis, a fatal coronavirus infection in cats, was successfully treated previously with a prodrug GC376, a dipeptide-based protease inhibitor. Here, we show the prodrug and its parent GC373, are effective inhibitors of the Mprofrom both SARS-CoV and SARS-CoV-2 with IC50values in the nanomolar range. Crystal structures of SARS-CoV-2 Mprowith these inhibitors have a covalent modification of the nucleophilic Cys145. NMR analysis reveals that inhibition proceeds via reversible formation of a hemithioacetal. GC373 and GC376 are potent inhibitors of SARS-CoV-2 replication in cell culture. They are strong drug candidates for the treatment of human coronavirus infections because they have already been successful in animals. The work here lays the framework for their use in human trials for the treatment of COVID-19.
- 10 December 2019
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 21 (24) , 10149-10153
Synthesis of Chiral Spin-Labeled Amino Acids
Spin-labeled amino acids (SLAAs) are often used to determine intermolecular distances and conformations in proteins via double electron–electron resonance. Currently available SLAAs can be difficult to incorporate selectively and have little resemblance to natural side chains in proteins. Enantioselective synthesis of three spin-labeled l-amino acids is described, starting from readily available 2,2,6,6-tetramethyl-4-piperidinone. These SLAAs better replicate canonical residues in proteins and aim for biological incorporation via genetic incorporation or solid-phase peptide synthesis.
- 10 December 2019
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 21 (24) , 10149-10153
Synthesis of Chiral Spin-Labeled Amino Acids
Spin-labeled amino acids (SLAAs) are often used to determine intermolecular distances and conformations in proteins via double electron–electron resonance. Currently available SLAAs can be difficult to incorporate selectively and have little resemblance to natural side chains in proteins. Enantioselective synthesis of three spin-labeled l-amino acids is described, starting from readily available 2,2,6,6-tetramethyl-4-piperidinone. These SLAAs better replicate canonical residues in proteins and aim for biological incorporation via genetic incorporation or solid-phase peptide synthesis.